Home Tags HER2

Tag: HER2

DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...

DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...

MI130004 Shows Positive in vivo Activity against HER2-Expressing Tumors

Positive results of MI130004, a novel antibody-drug conjugate combining trastuzumab via Cys residues through a non-hydrolysable linker, with PM050489, a molecule of marine origin,...

Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...

About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...

First Patient Dosed in Pivotal Phase II DESTINY-Gastric01 Study of DS-8201

A first patient has been enrolled in DESTINY-Gastric01 (NCT03329690), a pivotal phase II study in Japan and South Korea evaluating the safety and efficacy...

Alteogen Expects to Initiate Phase I trial of novel HER2 targeting...

In late august, Korean-based Alteogen announced that it expect to initiate a phase I clinical trial for ALT-P7, a novel antibody-drug conjugate or ADC...

Pivotal Phase II Study of DS-8201 in Patients with HER2-Positive Metastatic...

Researchers at Daichi Sankyo initiation the DESTINY-Breast01, a pivotal phase II study evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting antibody-drug conjugate...

Study Shows Therapeutic Potential of an anti-HER2 single chain antibody–DM1 conjugates

In an attempt to develop a more effective therapy for human epidermal growth factor receptor 2 (HER2)-positive cancer, a team of researchers led by...

First Patient with Advanced Solid Tumors with HER2 Expression Dosed in...

A first patient with advanced solid tumors with HER2 Expression was dosed in a phase I clinical trial with ADCT-502. The investigational drug being...

Bridging HER2 and Prolactin Receptor Improves Efficacy of an HER2 ADCs.

Authors: Andreev J, Thambi N, Perez Bay AE, Delfino FJ, Martin JH, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, MacDonald D,...
Featured Image: Doctor explaining diagnosis to her patient Courtesy: © 2017 Fotolia. Used with permission.

MM-302 Misses Endpoint in Phase II Hermione Trial

Following a recent independent Data and Safety Monitoring Board (DSMB) recommendation and subsequent futility analysis, Cambridge, Massachusetts-based Merrimack Pharmaceuticals, has decided to stop the...

X